source
- Lilly, Gilead lead pharma’s M&A boomDeal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.
- Top young AI researchers avoid careers at large pharmaceutical companiesMazdak Abulnaga, a 33‑year‑old postdoctoral fellow at MIT and Harvard Medical School, is highlighted as the type of employee pharmaceutical companies hope to attract this year. Despite the demand,…